Market Overview:
The global pediatric chronic rhinosinusitis treatment market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to factors such as rising prevalence of chronic rhinosinusitis in children, increasing awareness about available treatments, and growing demand for minimally invasive procedures. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. Based on type, the global pediatric chronic rhinosinusitis treatment market is segmented into steroids, antibiotics, antifungal therapy and others. Antibiotics are expected to dominate this market during the forecast period owing to their high efficacy in treating chronic sinus infections in children. Based on application, hospital pharmacies accounted for majority share of this market in 2017 and are projected to maintain their dominance during the forecast period. This can be attributed to increasing number of hospitals offering paediatric ENT services across regions worldwide coupled with rising adoption rates for minimally invasive procedures among paediatric population globally . However , retail pharmacies are anticipatedto witness highest CAGR over 2018-2030 due its growing popularity among parents as they offer convenience regarding location and timings .
Product Definition:
Pediatric chronic rhinosinusitis is a long-term inflammation of the sinuses in children. It can cause difficulty breathing, headaches, and a decreased sense of smell. Treatment includes antibiotics, nasal sprays, and surgery. The importance of pediatric chronic rhinosinusitis treatment is that it can improve the child's quality of life by relieving symptoms.
Steroids:
Steroids are man-made chemicals that are extracted from animal or plant sources and used to treat a medical condition. They can be administered in various forms such as nasal, oral, injectable or transdermal.
Antibiotics:
Antibiotics Market Size, Share & Trends Analysis Report By Type (Penicillin, Cephalosporin), By Application (Chronic Sinusitis), And Segment Forecasts, 2019 - 2026 -> The global antibiotics market size was valued at USD 13.5 billion in 2018 and is expected to grow at a compound annual growth rate (CAGR) of 3.8% from 2019 to 2026.
Application Insights:
Based on application, the global market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as presence of a large patient base with chronic rhinosinusitis and increasing prevalence of target diseases. Moreover, hospitals form an important part of society that deal with a wide range of health issues which encourages people to use healthcare services thereby promoting pharma sales through this channel.
The online pharmacy is anticipated to grow at fastest rate during forecast years owing to several advantages associated with it such as convenience and accessibility along with low cost compared to other channels for purchasing medicines.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of key players, favorable reimbursement scenario, and increasing healthcare expenditure are some factors contributing to the growth of this regional market. In addition, growing awareness about chronic sinusitis treatment options among patients and their parents is expected to drive demand for these products over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure by governments as well as private organizations in order to improve public health system and infrastructure coupled with an increase in consumer awareness regarding chronic rhinosinusitis treatment options. Moreover, economic development has led to improvement in living standards which has resulted into increased incidence rates of infectious diseases such as sinusitis that require prompt medical attention; thus driving CRS therapy demand across this region during the forecast period.
Growth Factors:
- Increasing incidence of pediatric chronic rhinosinusitis (CRS) due to changing lifestyle and environmental factors.
- Growing awareness about the symptoms and diagnosis of pediatric CRS among parents and physicians.
- Rising demand for minimally invasive sinus surgery procedures for the treatment of pediatric CRS.
- increasing prevalence of allergic rhinitis, one of the major risk factors for developing pediatric CRS 5 Increased funding for research on new therapies and treatments for pediatric CRS
Scope Of The Report
Report Attributes
Report Details
Report Title
Pediatric Chronic Rhinosinusitis Treatment Market Research Report
By Type
Steroids, Antibiotics, Antifungal Therapy, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer, Bayer, Novartis, Sanofi, AstraZeneca, Teva Pharmaceutical, Sumitomo Dainippon Pharma, Cipla, Lyra Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Pediatric Chronic Rhinosinusitis Treatment Market Report Segments:
The global Pediatric Chronic Rhinosinusitis Treatment market is segmented on the basis of:
Types
Steroids, Antibiotics, Antifungal Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Bayer
- Novartis
- Sanofi
- AstraZeneca
- Teva Pharmaceutical
- Sumitomo Dainippon Pharma
- Cipla
- Lyra Therapeutics
Highlights of The Pediatric Chronic Rhinosinusitis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Steroids
- Antibiotics
- Antifungal Therapy
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pediatric Chronic Rhinosinusitis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pediatric chronic rhinosinusitis treatment typically includes antibiotics, nasal steroids, and other medications. Surgery may also be necessary in some cases.
Some of the key players operating in the pediatric chronic rhinosinusitis treatment market are Pfizer, Bayer, Novartis, Sanofi, AstraZeneca, Teva Pharmaceutical, Sumitomo Dainippon Pharma, Cipla, Lyra Therapeutics.
The pediatric chronic rhinosinusitis treatment market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pediatric Chronic Rhinosinusitis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pediatric Chronic Rhinosinusitis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pediatric Chronic Rhinosinusitis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pediatric Chronic Rhinosinusitis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pediatric Chronic Rhinosinusitis Treatment Market Size & Forecast, 2018-2028
4.5.1 Pediatric Chronic Rhinosinusitis Treatment Market Size and Y-o-Y Growth
4.5.2 Pediatric Chronic Rhinosinusitis Treatment Market Absolute $ Opportunity
Chapter 5 Global Pediatric Chronic Rhinosinusitis Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Type
5.2.1 Steroids
5.2.2 Antibiotics
5.2.3 Antifungal Therapy
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pediatric Chronic Rhinosinusitis Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Online Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pediatric Chronic Rhinosinusitis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pediatric Chronic Rhinosinusitis Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Type
9.6.1 Steroids
9.6.2 Antibiotics
9.6.3 Antifungal Therapy
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Online Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pediatric Chronic Rhinosinusitis Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Type
10.6.1 Steroids
10.6.2 Antibiotics
10.6.3 Antifungal Therapy
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Online Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pediatric Chronic Rhinosinusitis Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Type
11.6.1 Steroids
11.6.2 Antibiotics
11.6.3 Antifungal Therapy
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Online Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pediatric Chronic Rhinosinusitis Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Type
12.6.1 Steroids
12.6.2 Antibiotics
12.6.3 Antifungal Therapy
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Online Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pediatric Chronic Rhinosinusitis Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Type
13.6.1 Steroids
13.6.2 Antibiotics
13.6.3 Antifungal Therapy
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pediatric Chronic Rhinosinusitis Treatment Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Online Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pediatric Chronic Rhinosinusitis Treatment Market: Competitive Dashboard
14.2 Global Pediatric Chronic Rhinosinusitis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Bayer
14.3.3 Novartis
14.3.4 Sanofi
14.3.5 AstraZeneca
14.3.6 Teva Pharmaceutical
14.3.7 Sumitomo Dainippon Pharma
14.3.8 Cipla
14.3.9 Lyra Therapeutics
